Introduction {#sec1}
============

Osteoarthritis (OA) is a clinical syndrome of joint pain and dysfunction that attacks millions of people \[[@B1]\]. OA is responsible for activity limitations, particularly walking, and affects participation and quality of life \[[@B2]\]. Amongst the weight-bearing joints, the knee is the most frequent-occurring place of OA \[[@B3]\]. However, the etiological factors involved in OA remain unclear. Obesity is reportedly a primary risk factor for knee OA \[[@B4]\]. Age, sex, body mass index (BMI), and repetitive joint activity are all involved in OA development \[[@B7],[@B8]\]. In addition to age, excessive BMI, joint surgery, and trauma that are recognized as the causes of OA, genome-wide association studies show genetic factors also contribute to OA development \[[@B9]\]. Therefore, environmental factors, genetic factors, and their interactions are associated with OA susceptibility \[[@B12],[@B13]\].

Adipose tissues, an active endocrine organ, release some adipokines that are pivotal in bone formation and bone absorption, including adiponectin (ADIPOQ), leptin, and visfatin \[[@B14]\]. Adipokines can stimulate the secretion of interleukin (IL)-6/8 and prostaglandin E2 in synovial fibroblasts \[[@B15]\], and are implicated in the development and progression of OA \[[@B18]\]. ADIPOQ level is associated with radiographic changes and progression of rheumatoid arthritis \[[@B19],[@B20]\], and with cartilage destruction in OA patients \[[@B21]\]. Synovial fluid ADIPOQ level can promote inflammation in OA patients and contribute to OA-related metabolic changes \[[@B22]\]. ADIPOQ is also linked with cartilage loss \[[@B23]\]. Serum ADIPOQ level could be used as a biomarker of OA \[[@B24]\]. A recent meta-analysis shows that ADIPOQ levels are higher in OA patients than in healthy controls \[[@B25]\], which suggests an important role of ADIPOQ in OA development.

Recently, several studies have explored the association between ADIPOQ gene polymorphisms and OA risk \[[@B26]\], but present contradictory and inconclusive findings. Thus, this case--control study was conducted to verify such relationship in a Chinese Han population.

Materials and methods {#sec2}
=====================

Patients {#sec2-1}
--------

A total of 372 knee OA patients were selected from Huai'an First People's Hospital from July 2013 to June 2017. According to the criteria of the American College of Rheumatology, primary OA was diagnosed as any symptom and sign of OA as well as radiographic signs of OA based on the Kellgren--Lawrence (K-L) grade \[[@B29]\]. Exclusion criteria were as follows: (i) ankylosing spondylitis, psorasis, and other autoimmune diseases; (ii) previous knee injury or joint infection; (iii) alcohol abuse for more than 6 months. A total of 453 healthy controls without family history of OA were recruited from the patients who attended the general surgery of the same hospital at the same time period. Any individual with a positive history of tumor, other arthritis or joint diseases, or other inflammatory or chronic infectious symptoms was excluded. All subjects were from the same ethnic and geographical origins, and there was no genetic relationship between groups. The clinical characteristics of all OA patients and controls including sex, age, K-L grade, and BMI were extracted from medical records. Informed consents were obtained from all participants before the research. The study protocol was approved by the Institutional Review Board of the Hospital. The present study was carried out in accordance with the World Medical Association Declaration of Helsinki.

DNA extraction and genotyping {#sec2-2}
-----------------------------

Blood samples (each 2 ml) were collected in vacutainer tubes and transferred to EDTA tubes. Genomic DNA was extracted from the peripheral blood (each sample 300 μl) using a QIAamp DNA blood mini-kit (Qiagen, Hilden, Germany). The selective single-nucleotide polymorphism (SNP) was genotyped via standard PCR and restriction fragment length polymorphism (PCR-RFLP). The following forward and reverse primers were used: 5′-ACACTGATATAAACGCCATGAA­-3′ and 5′-­GCAGCAAAGCCAAAGTCTTC-­3′. In brief, a PCR system (50 μl) consisted of 10× PCR buffer for KOD-Plus-Neo (5 μl), ddH~2~O (34 μl), primers (each 1 μl), template (1 μl), 2 mM dNTPs (5 μl), 25 mM MgSO~4~ (3 μl), cDNA (1 μl), and KOD-Plus-Neo (TOYOBO, Japan, 1 μl). Reaction conditions were: 95°C, 5 min; 94°C, 30 s; 50°C, 30 s; 72°C, 1 min, 35 cycles; 72°C, 10 min for extension, cooling to 4°C. The PCR products were digested with BglI (New England Biolabs, Beverly, MA) at 37°C for 5 h and then detected via 2% agarose gel electrophoresis. Approximately 5% of the samples were randomly chosen for a second run to validate the accuracy of the genotyping results. All duplicate samples showed a concordance rate of 100%.

ELISA {#sec2-3}
-----

Plasma ADIPOQ levels were determined with an ADIPOQ (Human) ELISA kit (Shanghai Qunji Biotech Co., Ltd, China) and calculated by referring to a standard curve.

Statistical analysis {#sec2-4}
--------------------

The differences in demographic variables, allele frequencies, and genotypes amongst all individuals were assessed via Chi-squared (χ^2^) test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression analysis. The Hardy--Weinberg equilibrium (HWE) amongst controls was examined by a goodness-of- fit χ^2^ test. Plasma ADIPOQ levels for genotypes were analyzed by one-way ANOVA and Student's *t*test. All statistical analyses were performed on SAS 9.1.3 (SAS Institute, Cary, NC, U.S.A.).

Results {#sec3}
=======

Characteristics of the study population {#sec3-1}
---------------------------------------

The detailed characteristics of all individuals and the K-L grades of OA cases were summarized in [Table 1](#T1){ref-type="table"}. The mean ages of the cases and controls were 50.23 and 51.12 year, respectively. The female to male ratio of OA cases was 57.5%:42.5%. The mean BMI of cases was 25.01 kg/m^2^. No significant differences in sex, age, or BMI were found between the OA patients and controls. The OA patients showed significantly higher ADIPOQ levels than the controls (*P*=0.022).

###### Subject demographics and risk factors in knee OA

  Variables               Patients (*n*=372)   Controls (*n*=453)   *P*
  ----------------------- -------------------- -------------------- -----------
  Sex                                                               0.674
    Male                  158 (42.5%)          199 (43.9%)          
    Female                214 (57.5%)          254 (56.1%)          
  Age (years)             50.23 ± 10.91        51.12 ± 9.93         0.880
  BMI (kg/m^2^)           25.01 ± 1.71         25.04 ± 1.52         0.779
  K-L grade                                                         
    1                     73 (19.6%)           \-                   \-
    2                     121 (32.5%)          \-                   \-
    3                     155 (41.7%)          \-                   \-
    4                     23 (6.2%)            \-                   \-
  ADIPOQ levels (μg/ml)   5.53 ± 3.54          3.70 ± 2.36          **0.022**

Values in bold are statistically significant (*P* \<0.05).

ADIPOQ levels were available in 30 OA patients (TT: 10; TG: 10; GG: 10) and 30 healthy controls (TT: 10; TG: 10; GG: 10).

Association between ADIPOQ gene rs1501299 polymorphism and knee OA risk {#sec3-2}
-----------------------------------------------------------------------

Genotype distributions of ADIPOQ gene rs1501299 polymorphism in the control group conformed to HWE (*P*=0.566; [Table 2](#T2){ref-type="table"}). Logistic regression analyses showed TT genotype of this polymorphism significantly increased the risk of knee OA (TT vs. GG: adjusted OR and 95% CI, 1.70 (1.01--2.89), *P*=0.046) ([Table 2](#T2){ref-type="table"}). The allele genetic analysis showed T allele was associated with an increased risk of knee OA ([Table 2](#T2){ref-type="table"}).

###### Logistic regression analysis of associations between rs1501299 polymorphism and risk of knee OA

  Genotype       Cases[\*](#T2TFN1){ref-type="table-fn"} (*n*=372)   Controls[\*](#T2TFN1){ref-type="table-fn"} (*n*=453)   OR (95% CI); *P*   Adjusted OR (95% CI); *P*                                  
  -------------- --------------------------------------------------- ------------------------------------------------------ ------------------ --------------------------- ------------------------------ ------------------------------
  GT vs. GG      160/174                                             42.7/46.8                                              182/240            40.2/53.0                   1.21 (0.91, 1.62); 0.190       1.21 (0.91, 1.62); 0.187
  TT vs. GG      37/174                                              9.9/46.8                                               30/240             6.6/53.0                    **1.70 (1.01, 2.86);** 0.045   **1.70 (1.01, 2.89);** 0.046
  TT+GT vs. GG   197/174                                             52.6/46.8                                              212/240            46.8/53.0                   1.28 (0.97, 1.69); 0.077       1.28 (0.97,1.69); 0.076
  TT vs. GT+GG   37/334                                              9.9/89.5                                               30/422             6.6/93.2                    1.56 (0.94, 2.58); 0.084       1.55 (0.94, 2.57); 0.085
  T vs. G        234/508                                             31.3/68.1                                              242/662            26.7/73.1                   **1.26 (1.02, 1.56);** 0.034   

The genotyping was successful in 371 cases and 452 controls.

Bold values are statistically significant (*P*\<0.05).

Subgroup analyses of clinical and biochemical characteristics were also performed between groups. Significant associations were obtained in subgroups of ≥55 years (TT vs.GG: adjusted OR and 95% CI, 2.21 (1.00--4.86), *P*=0.049) and BMI \< 25 kg/m^2^, but not in the analysis of sex ([Table 3](#T3){ref-type="table"}). The ADIPOQ level analyses in different genotypes of OA patients revealed no significant association between ADIPOQ rs1501299 polymorphism and ADIPOQ concentration ([Figure 1](#F1){ref-type="fig"}). Furthermore, the ADIPOQ rs1501299 polymorphism did not significantly affect the K-L grades of OA patients ([Table 4](#T4){ref-type="table"}).

![The ADIPOQ levels in different genotypes](bsr-39-bsr20182104-g1){#F1}

###### The clinical and biochemical characteristics of rs1501299 polymorphism amongst two groups

  Variable        rs1501299 (case/control)   GT vs. GG   TT vs. GG   TT+GT vs. GG               TT vs. GT+GG                                                  
  --------------- -------------------------- ----------- ----------- -------------------------- ------------------------------ ------------------------------ --------------------------
  Sex                                                                                                                                                         
    Male          75/101                     67/86       15/11       1.05 (0.68, 1.63); 0.830   1.84 (0.80, 4.23); 0.153       1.14 (0.75, 1.73); 0.544       1.80 (0.80, 4.03); 0.156
    Female        99/139                     93/96       22/19       1.36 (0.93, 2.00); 0.117   1.63 (0.84, 3.16); 0.153       1.40 (0.98, 2.02); 0.068       1.42 (0.75, 2.70); 0.288
  Age (years)                                                                                                                                                 
    \<55          108/148                    100/107     18/18       1.28 (0.89, 1.85); 0.188   1.37 (0.68, 2.76); 0.377       1.29 (0.91, 1.84); 0.153       1.23 (0.62, 2.42); 0.556
    ≥55           66/92                      60/75       19/12       1.12 (0.70, 1.77); 0.645   **2.21 (1.00, 4.86); 0.049**   1.27 (0.82, 1.96); 0.293       2.10 (0.98, 4.48); 0.056
  BMI (kg/m^2^)                                                                                                                                               
    \<25          78/116                     84/84       17/14       1.49 (0.98, 2.26); 0.062   1.81 (0.84, 3.87); 0.129       **1.53 (1.03, 2.29); 0.036**   1.50 (0.72, 3.13); 0.282
    ≥25           96/124                     76/98       20/16       1.00 (0.67, 1.50); 0.993   1.62 (0.79, 3.28); 0.186       1.09 (0.74, 1.59); 0.665       1.61 (0.81, 3.21); 0.172

Bold values are statistically significant (*P*\<0.05).

###### The associations between ADIPOQ rs1501299 polymorphism and clinical characteristics of knee OA

  Characteristics          Genotype distributions   TT                         GT+TT                      G                          T                  
  ------------------------ ------------------------ -------------------------- -------------------------- -------------------------- ------------------ --------------------------
  K-L grade                                                                                                                                             
  3+4/1+2                  77/97                    81/79                      20/17                      101/96                     235/273            121/113
  OR (95% CI); *P*-value   1.0 (reference)          1.29 (0.84, 1.99); 0.244   1.48 (0.73, 3.02); 0.279   1.33 (0.88, 2.00); 0.177   1.00 (reference)   1.24 (0.91, 1.70); 0.168

Discussion {#sec4}
==========

This case--control study showed the ADIPOQ gene rs1501299 polymorphism was significantly associated with an increased risk of knee OA. Similar associations were obtained in subgroups ≥55 years and BMI \< 25 kg/m^2^.

A cross-sectional study from Finland found no relation between four ADIPOQ gene polymorphisms (including rs1501299 polymorphism) and the risk of hand OA \[[@B26]\]. Zhan et al. \[[@B27]\] from Thailand also revealed significant association between the rs1501299 genotype distribution and KL grades 2, 3, or 4, but not between ADIPOQ rs2241766 or rs1501299 polymorphism and knee OA risk. Another study from Spain indicated ADIPOQ gene rs1501299 polymorphisms were not associated with cardiovascular disease in rheumatoid arthritis patients \[[@B30]\], though it was not knee OA. A recent Chinese study indicated only the ADIPOQ gene rs182052 polymorphism amongst three tested SNPs was associated with OA risk \[[@B28]\]. Here we observed ADIPOQ gene rs1501299 polymorphism increased the risk of knee OA. To our knowledge, this is the first study to report the relation between an increased risk of OA and rs1501299 polymorphism. We hypothesized the conflicting findings amongst the above studies and the present study may be attributed to five reasons. The first potential reason was the genetic heterogeneity between Asians and Caucasians. The second one may be the clinical heterogeneity. Specifically, the study from Finland enrolled hand OA of 542 occupationally active Finnish female dentists and teachers \[[@B26]\], but we focussed on knee OA. Probably rs1501299 polymorphism was a specific locus for knee OA, but not hand OA. Third, the sample sizes varied amongst these studies, but small sample sizes may lead to false-positive results. We included 372 OA patients, while Jiang et al. only enrolled 172 OA cases \[[@B28]\]. Fourth, various occupations or body weight may also be a reason. Last but not the least, genotyping methods may also be an influencing factor. The interaction between genes and environmental factors plays a predominant role in the pathogenesis of genetic diseases. Subgroup analyses of clinical and biochemical characteristics showed significant associations in the subgroups of ≥55 years and BMI \< 25 kg/m^2^, indicating these individuals were more prone to these risk factors.

Some limitations of this case--control study need to be considered. First, we only investigated one SNP of ADIPOQ gene, which called for research on other SNPs. Second, the sample size was not large enough. Third, whether ADIPOQ gene polymorphism altered the protein expression was not explored. Fourth, OA in the hip or hand joints should be further studied. Fifth, though an association in ADIPOQ gene polymorphism was observed, we did not know how this gene polymorphism influenced the knee OA development. Finally, ADIPOQ gene polymorphisms interacting with environmental factors should be explored in the future.

In conclusion, the ADIPOQ gene rs1501299 polymorphism is associated with an increased risk of knee OA in a Chinese Han population. Nevertheless, this finding should be validated by well-designed larger size case--control studies involving other populations and other joints.

Author contribution {#sec5}
===================

Conceived and designed the experiments: H.S., Y.H., W.H., and Q.J. Performed the experiments: H.S. and X.H. Analyzed the data: W.H. Contributed reagents/materials/analysis tools: W.H. and X.H. Wrote the paper: H.S. and Q.J.

Funding {#sec6}
=======

The authors declare that there are no sources of funding to be acknowledged.

Competing interests {#sec7}
===================

The authors declare that there are no competing interests associated with the manuscript.

ADIPOQ

:   adiponectin

BMI

:   body mass index

CI

:   confidence interval

HWE

:   Hardy--Weinberg equilibrium

K-L

:   Kellgren--Lawrence

OA

:   osteoarthritis

OR

:   odds ratio

SNP

:   single-nucleotide polymorphism
